MedTrace Logo

A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test

NCT00762658 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-02-22

No results posted yet for this study

Summary

To investigate dose-response relationship, antipsoriatic efficacy and safety of different concentrations of topical formulations of AN2728 in patients with psoriasis vulgaris

Conditions

Interventions

DRUG

AN2728 Ointment, 5%

DRUG

AN2728 Ointment, 2%

DRUG

AN2728 Ointment, 0.5%

DRUG

AN2728 Ointment Vehicle

DRUG

Betnesol®-V Creme, 0.1%

DRUG

Protopic® Ointment, 0.1 %

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2007-12-07
Completion
2007-12-07

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00762658 on ClinicalTrials.gov